1. Home
  2. MBRX
  3. MBRX News

Latest Moleculin Biotech Inc. (MBRX) News on August 17, 2025

MBRX

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 06/24/2025

Moleculin Biotech prices 16.08M shares at 37c in public offering
MBRX

TipRanks

2 months ago

Moleculin Biotech prices 16.08M shares at 37c in public offering

MBRX

MT Newswires

2 months ago

Top Midday Decliners

MBRX

MT Newswires

2 months ago

Moleculin Biotech Prices $5.9 Million Offering of Shares, Warrants

Moleculin Announces $5.9 Million Public Offering
MBRX

GlobeNewswire

2 months ago

Moleculin Announces $5.9 Million Public Offering

Moleculin Participates in Virtual Investor “What This Means” Segment
MBRX

GlobeNewswire

2 months ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
MBRX

GlobeNewswire

2 months ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Moleculin Biotech announces ‘What This Means’ virtual investor segment
MBRX

TipRanks

2 months ago

Moleculin Biotech announces ‘What This Means’ virtual investor segment

Moleculin Participates in Virtual Investor “What This Means” Segment
MBRX

GlobeNewswire

2 months ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
MBRX

GlobeNewswire

2 months ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

MBRX

MT Newswires

2 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

MBRX

MT Newswires

2 months ago

Moleculin Biotech Shares Slump After Phase 1b/2 Trial of Annamycin Fails to Show Complete Responses

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
MBRX

GlobeNewswire

2 months ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ...
MBRX

GuruFocus.com

3 months ago

Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ...

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
MBRX

GlobeNewswire

3 months ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

EMA approves Moleculin’s application for Phase IIb/III AML trial
MBRX

Clinical Trials Arena

3 months ago

EMA approves Moleculin’s application for Phase IIb/III AML trial

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
MBRX

GlobeNewswire

3 months ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast
MBRX

GlobeNewswire

3 months ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin
MBRX

GlobeNewswire

3 months ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents
MBRX

GlobeNewswire

3 months ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
MBRX

GlobeNewswire

4 months ago

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
MBRX

GlobeNewswire

4 months ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial
MBRX

TipRanks

4 months ago

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial

Moleculin Biotech begins dosing subjects in combination therapy trial for AML
MBRX

Clinical Trials Arena

4 months ago

Moleculin Biotech begins dosing subjects in combination therapy trial for AML

Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now
MBRX

Zacks

5 months ago

Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
MBRX

GlobeNewswire

5 months ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy
MBRX

Zacks

5 months ago

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ...
MBRX

GuruFocus.com

5 months ago

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ...

MBRX

Thomson Reuters StreetEvents

5 months ago

Q4 2024 Moleculin Biotech Inc Earnings Call

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
MBRX

GlobeNewswire

5 months ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
MBRX

GlobeNewswire

5 months ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
MBRX

PR Newswire

5 months ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin to Present at the 37th Annual ROTH Conference
MBRX

PR Newswire

5 months ago

Moleculin to Present at the 37th Annual ROTH Conference

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity
MBRX

PR Newswire

5 months ago

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
MBRX

PR Newswire

5 months ago

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

MBRX

MT Newswires

6 months ago

Moleculin Biotech Prices $3.5 Million Direct Offering; Shares Rise

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules
MBRX

PR Newswire

6 months ago

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

MBRX

MT Newswires

6 months ago

Moleculin Biotech Expects to Raise $5.8 Million From Exercise of Warrants

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?
MBRX

Benzinga

6 months ago

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds
MBRX

PR Newswire

6 months ago

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)
MBRX

PR Newswire

6 months ago

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine
MBRX

Clinical Trials Arena

6 months ago

Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine

MBRX

MT Newswires

6 months ago

Moleculin Biotech Receives Approval in Ukraine to Start Recruiting for Acute Myeloid Leukemia Phase 3 Trial

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial
MBRX

PR Newswire

6 months ago

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Moleculin Participates in Virtual Investor "What This Means" Segment
MBRX

PR Newswire

7 months ago

Moleculin Participates in Virtual Investor "What This Means" Segment

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026
MBRX

PR Newswire

7 months ago

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

MBRX

MT Newswires

8 months ago

Moleculin Biotech Shares Rise After Announcing Preclinical Data for Annamycin Targeting Venetoclax-Resistant Leukemia

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model
MBRX

PR Newswire

8 months ago

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
MBRX

PR Newswire

9 months ago

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
MBRX

PR Newswire

9 months ago

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Biotech Reports Financial Highlights and Future Plans
MBRX

TipRanks

9 months ago

Moleculin Biotech Reports Financial Highlights and Future Plans

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
MBRX

PR Newswire

9 months ago

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

MBRX

Thomson Reuters StreetEvents

9 months ago

Q3 2024 Moleculin Biotech Inc Earnings Call

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
MBRX

PR Newswire

9 months ago

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast
MBRX

PR Newswire

9 months ago

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin
MBRX

PR Newswire

9 months ago

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Moleculin Biotech Highlights Annamycin’s AML Treatment Potential
MBRX

TipRanks

10 months ago

Moleculin Biotech Highlights Annamycin’s AML Treatment Potential

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available
MBRX

PR Newswire

10 months ago

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...
MBRX

GuruFocus.com

10 months ago

Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
MBRX

PR Newswire

10 months ago

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

Moleculin to Present at Two Upcoming Investor Conferences
MBRX

PR Newswire

10 months ago

Moleculin to Present at Two Upcoming Investor Conferences

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
MBRX

PR Newswire

a year ago

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

Moleculin Participates in Virtual Investor "What this Means" Segment
MBRX

PR Newswire

a year ago

Moleculin Participates in Virtual Investor "What this Means" Segment

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
MBRX

PR Newswire

a year ago

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MBRX

PR Newswire

a year ago

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
MBRX

PR Newswire

a year ago

Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Moleculin Announces Closing of up to $16.5 Million Public Offering
MBRX

PR Newswire

a year ago

Moleculin Announces Closing of up to $16.5 Million Public Offering

MBRX

MT Newswires

a year ago

Moleculin Biotech Prices Up to $16.5 Million Public Offering

Moleculin Announces Pricing of up to $16.5 Million Public Offering
MBRX

PR Newswire

a year ago

Moleculin Announces Pricing of up to $16.5 Million Public Offering

Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
MBRX

PR Newswire

a year ago

Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial
MBRX

PR Newswire

a year ago

Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
MBRX

PR Newswire

a year ago

Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
MBRX

PR Newswire

a year ago

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

Moleculin to Present at the Virtual Investor Pitch Conference
MBRX

PR Newswire

a year ago

Moleculin to Present at the Virtual Investor Pitch Conference

Moleculin to Participate in the Virtual Investor Lunch Break Series
MBRX

PR Newswire

a year ago

Moleculin to Participate in the Virtual Investor Lunch Break Series

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
MBRX

PR Newswire

a year ago

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress

Moleculin begins NIH-funded Phase II glioblastoma treatment trial
MBRX

Clinical Trials Arena

a year ago

Moleculin begins NIH-funded Phase II glioblastoma treatment trial

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
MBRX

PR Newswire

a year ago

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

MBRX

GuruFocus.com

a year ago

Moleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
MBRX

PR Newswire

a year ago

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
MBRX

PR Newswire

a year ago

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
MBRX

PR Newswire

a year ago

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
MBRX

PR Newswire

a year ago

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
MBRX

PR Newswire

a year ago

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
MBRX

PR Newswire

a year ago

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
MBRX

ACCESSWIRE

a year ago

Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
MBRX

PR Newswire

a year ago

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
MBRX

PR Newswire

a year ago

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
MBRX

PR Newswire

a year ago

Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
MBRX

PR Newswire

a year ago

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
MBRX

PR Newswire

a year ago

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript
MBRX

Insider Monkey

a year ago

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript

Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
MBRX

PR Newswire

a year ago

Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

Moleculin Biotech Inc Reports Fiscal Year 2023 Financial Results
MBRX

GuruFocus.com

a year ago

Moleculin Biotech Inc Reports Fiscal Year 2023 Financial Results

Moleculin Reports Full Year 2023 Financial Results
MBRX

PR Newswire

a year ago

Moleculin Reports Full Year 2023 Financial Results

Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
MBRX

PR Newswire

a year ago

Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast

Moleculin Announces Reverse Stock Split
MBRX

PR Newswire

a year ago

Moleculin Announces Reverse Stock Split

Moleculin to Present at the 36th Annual ROTH Conference
MBRX

PR Newswire

a year ago

Moleculin to Present at the 36th Annual ROTH Conference

An Intrinsic Calculation For Information Services Corporation (TSE:ISV) Suggests It's 45% Undervalued
MBRX

Simply Wall St.

2 years ago

An Intrinsic Calculation For Information Services Corporation (TSE:ISV) Suggests It's 45% Undervalued

Palatin Announces $10 Million Registered Direct Offering
MBRX

PR Newswire

2 years ago

Palatin Announces $10 Million Registered Direct Offering

Share on Social Networks: